| 产品编号 | BIO1001SM |
| 英文名称 | Anti-CD3 & GD2 Reference Antibody (Nivatrotamab Biosimilar) |
| 别 名 | CD3 & GD2; Nivatrotamab |
| 抗体来源 | |
| 克隆类型 | Monoclonal |
| 交叉反应 | Human |
| 产品应用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 200.96kDa |
| 性 状 | Lyophilized |
| 亚 型 | IgG-ScFv |
| 纯化方法 | Protein A |
| 缓 冲 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存条件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 | |
| 产品图片 |
Co-incubation of Nivatrotamab with Jurkat cells, then with the addition of hu GD2-his-293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Nivatrotamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.979 nM.
Nivatrotamab bound to hu GD2-293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to hu GD2-293 cells, and the EC50 was 68.100 nM.
Nivatrotamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huCD3e-jurkat cells, and the EC50 was 3.481 nM.
The purity of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.
Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 200.83 kDa.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
